Vanguard Personalized Indexing Management, LLC Mirati Therapeutics, Inc. Transaction History

Vanguard Personalized Indexing Management, LLC

$4.59 Billion
Q1 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $35,462 - $51,673	596 Added 12.31%	5,439 $380,000
Q2 2022 Aug 09, 2022	BUY	$39.16 - $88.71 $64,927 - $147,081	1,658 Added 52.06%	4,843 $325,000
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $241,486 - $480,839	3,185 New	3,185 $262,000
Q4 2021 Feb 23, 2022	SELL	$132.01 - $190.29 $169,896 - $244,903	-1,287 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$132.13 - $177.45 $34,221 - $45,959	-259 Reduced 16.75%	1,287 $228,000

Q2 2021 Aug 11, 2021	BUY	$144.0 - $179.73 $222,624 - $277,862	1,546 New	1,546 $250,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Personalized Indexing Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Personalized Indexing Management, LLC with notifications on news.

Account